DIPROLENE AF Rx
Generic Name and Formulations:
Bethamethasone, augmented (as dipropionate) 0.05%; crm.
Merck & Co., Inc.
Indications for DIPROLENE AF:
≥13yrs: apply thin film 1–2 times daily; max 50g/week. Lotion: apply a few drops 1–2 times daily; max 50mL/week; max 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Do not occlude.
<13yrs: not recommended.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Erythema, folliculitis, pruritus, vesiculation; contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia. Also for AF crm: stinging, skin atrophy, telangiectasia, bruising, shininess.
Oint, AF crm—15g, 50g; Lotion—30mL, 60mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline